A Phase 2 interventional study of KLH-2109 and KLH-2109 in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-10-30.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.
Among the 10 studies testing linzagolix in Endometriosis, this one is one of 5 in phase 2, and was the 1st registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked.
This study's planned enrollment of 20 is below the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 100 across the 9 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 9 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing linzagolix in Endometriosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07015268Phase 3Kissei Pharmaceutical Co., Ltd.A Clinical Study of KLH-2109 in Patients With Endometriosis | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing linzagolix in Endometriosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The severity score of the pelvic pain
Time frame: 8 weeks
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linzagolix
Kissei Pharmaceutical Co., Ltd. →